Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ichnocim
- Development stage
- Phase 3
- Lead developer
- ImCheck Therapeutics
- Modality
- Antibody-Based Therapeutics
01
Overview
Ichnocim is a lead antibody developed by Imcheck Therapeutics. It is designed to activate gamma-delta T cells and was in Phase 1/2 clinical trials for cancer at the time of an investment by Andera Partners, through its BioDiscovery 6 fund. The investment specifically supports the clinical development of Imcheck's pipeline, which is based on activating gamma-delta T cells.
- Other names
- anti-BTN3A agonistic monoclonal antibody ICT01anti-BTN-3A agonistic monoclonal antibody ICT01anti-BTN 3A agonistic monoclonal antibody ICT01
02
Targets
BTN2A1 (Butyrophilin subfamily 2 member A1)BTN3A (Butyrophilin subfamily 3 member A)
Beyond the preview
Go deeper on Ichnocim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ichnocim.